DPP-1 inhibitor
Fosun Pharma Bets on DPP-1 Inhibition for Global Respiratory Market with $645M Out-Licensing Deal
On August 11, Fosun Pharma took another step in its strategy to globalize its innovation pipeline, out-licensing its oral small-molecule DPP-1 inhibitor XH-S004 to San Francisco-based Expedition Therapeutics for territories outside mainland China, Hong Kong, and Macau. The deal could be worth up to $645 million in upfront, milestone, and